

Strengthening Training for Academia in Regulatory Science (STARS) Project: The road so far

Dr. Viktorija Starokozhko

MEB Science Day 2022 February 17th 2022

under grant agreement No. 825881








Academic Drug Development

- Contribution of academia in drug discovery & ۲ development is increasing
- Especially in the field of advanced therapies ۲
- No EU academic drug marketing authorization holder ٠ till now




Year


Academic

Large company

SME


× Total





Sponsor variations in clinical gene- and cell-based therapy development







designed by icon



CSA-STARS: <u>Strengthening Training of Academia in Regulatory Sciences</u> & Supporting Regulatory Scientific Advice


- Consortium of 21 partners from 18 European countries represented via their NCA & EMA (plus 4 associated partners) and DLR-PT
- Funding by European Commission
- Project period: January 2019 June 2022








Interactions with Stakeholders –Communication is Key!










Mind the (Knowledge) Gap

A lot of support activities already exist:

- National level: Scientific Advice, Innovation Offices
- EU level: EMA's early development and advice services (Innovation Task Force, PRIME scheme, Scientific Advice, etc.)
- EU Innovation Network




Kallio et al., manuscript in preparation




Challenges in academia

- **Communication** with regulators: poor, high-bar, different "language"
- Poor awareness of regulatory guidance and support
- Lack of general regulatory knowledge
- Lack of **knowledge** on development & methodology in academia (e.g. Clinical Trial Application)
- **Time**: difficulties to ask the right questions at the right time
- **Complexity** of the regulatory process






Working Programme, Project Outcomes and Impact









Comprehensive Inventory (CI)

Comprehensive overview of support services for regulatory activities

Listing	<mark>y Expertise Are</mark>	a	•
Country 🝦	Provider Type	Expertise	Provider Details
Spain	National Competent Authority	ATMPs	<u>⊕</u> AEMPS
Belgium	Public Actor	ATMPs	<u> </u> <u> </u> <u> </u> Antwerp University Hospital
France	Public Actor	ATMPs	<u>⊕</u> AP-HP
Germany	Public Actor	ATMPs	
Austria	National Competent Authority	ATMPs	👲 BASG / AGES
France	Public Actor	ATMPs	🕹 CHU Amiens Picardie
Spain	Public Actor	ATMPs	🕹 CIBER
Switzerland	Public Actor	ATMPs	<u> </u>
Germany	Public Actor	ATMPs	<u> </u>
Europe	Public Actor	ATMPs	
Germany	Public Actor	ATMPs	
Czech Republic	Public Actor	ATMPs	. Czech Clinical Research Infrastructure Network
Europe	Public Actor	ATMPs	🕹 EATRIS


Country 🖕	Provider Type	Support 🔒 Activity	Provider Details
Portugal	Public Actor	Assistance in clinical trial application	👲 2CA-Braga
Spain	National Competent Authority	Assistance in clinical trial application	<u> </u>
Belgium	Public Actor	Assistance in clinical trial application	Antwerp University Hospital
France	Public Actor	Assistance in clinical trial application	<u>&</u> AP-HP
Germany	Public Actor	Assistance in clinical trial application	
Austria	National Competent Authority	Assistance in clinical trial application	👲 BASG / AGES
Germany	National Competent Authority	Assistance in clinical trial application	<u> </u>
Ireland	Public Actor	Assistance in clinical trial application	A Cancer Trials Ireland
Germany	Public Actor	Assistance in clinical trial application	<u>⊕</u> Center for Clinical Trials Tuebingen
France	Public Actor	Assistance in	👲 CHU Amiens Picardie

Direct support for clinical researcher! Visit our website: https://www.csa-stars.eu/Inventory-1721.html



Comprehensive Inventory







STARS White Paper & 1st Stakeholder Workshop Communication & Interaction Framework and its Gaps



Drug Discovery Today Volume 26, Issue 2, February 2021, Pages 283-288




Feature


Strengthening regulatory science in academia: STARS, an EU initiative to bridge the translational

gap

Viktoriia Starokozhko^{1, 2}, Marko Kallio³, Åsa Kumlin Howell⁴, Anna Mäkinen Salmi⁴, Gunilla Andrew-Nielsen⁴, M. Goldammer⁵, Manja Burggraf⁶, Wiebke Löbker⁷, Anne Böhmer⁷, Eleonora Agricola⁸, Corinne S. de Vries⁹, Anna M.G. Pasmooij¹, Peter G.M. Mol^{1, 2}, \cong , on behalf of the STARS consortium







Aim:


Continuous regulatory training

Exchange with the research

Starokozhko et al, Drug Discovery Today, 2021


NCAs: national competent authorities; EMA: European Medicines Agence







STARS Pilots





Pilot I Transfer of an identified best practice example




- Poor awareness of regulatory support tools
- Difficulty in reaching sufficient level of regulatory knowledge (with attention to CTA)

Topics of the online course:

- Regulatory system and framework
- Essential regulatory knowledge in drug development
- Specific Regulatory Knowledge for Advanced Therapy Medicinal Products (ATMPs)







Pilot II Initiation of a Novel Support Activity

STARS Survey data:

- Tool/s to improve the communication between regulators and academia
- Timely response is probably the most remarkable need

Concept: **one-stop-shop platform** for Spanish academia (September 2021)










Pilot Project II

Initiation of a novel support activity for improving success on regulatory Scientific Advice.











STARS Curricula










The STARS Common Strategy & 2^d Stakeholder Workshop



What is the Common Strategy?

Strategic document with recommendations to improve the regulatory knowledge, awareness and skills of academia

What does it include?


Recommendations based on survey data, evaluation of pilots, input from stakeholders

To whom adressed?

European Commission, stakeholder in Europe and member states, e.g. ministries, policy maker, funders, academia, NCAs and public



Drug Development - From Lab to Patient



designed by icon



Acknowledgement





This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825881

https://www.csa-stars.eu/index.html